Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

RECOVERY (Aspirin), 2022 NCT04381936

Aspirin (n=7351) vs. standard of care (n=7541)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Aspirin
Usual care plus 150mg aspirin once per day by mouth (or nasogastric tube) or by rectum until discharge.

Control treatment

Usual care

As a platform trial, and in a factorial design, patients could be simultaneously randomly assigned to the following other treatment groups: azithromycin, colchicine,or dimethyl fumarate versus usual care; convalescent plasma or casirivimab and imdevimab versus usual care; and baricitinib versus usual care. Until Jan 24, 2021, the trial also allowed asubsequent randomisation for patients with progressive COVID-19 (evidence of hypoxia and a hyperinflammatory state) to tocilizumab versus usual care. 210 patients (3%) allocated to usual care received at least one dose of aspirin.

Patients

COVID 19 hospitalized

Method

Open-label.

177 hospitals in the UK, 2 hospitals in Indonesia, and 2 hospitals in Nepal.

Remark